These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36765622)

  • 21. Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas.
    Roskoski R
    Pharmacol Res; 2017 Jun; 120():116-132. PubMed ID: 28330784
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunotherapeutic Innovations in Clear Cell Renal Cell Carcinoma: Current Strategies and Future Directions.
    Chipuc S; Bogdan H; Serban D; Badiu DC; Zgura A; Anghel R
    Cancer Diagn Progn; 2024; 4(5):558-562. PubMed ID: 39238630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mutational profile of primary clear cell renal cell carcinoma predicts recurrence and potential candidacy for adjuvant immune checkpoint inhibition.
    Vlachostergios PJ; Papathanassiou M; Anagnostou M; Thodou E; Tamposis I; Mitrakas L; Zachos I; Koukoulis GK; Samara M; Tzortzis V
    F1000Res; 2023; 12():918. PubMed ID: 38933491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Renal Cell Carcinoma in von Hippel-Lindau Disease-From Tumor Genetics to Novel Therapeutic Strategies.
    Kim E; Zschiedrich S
    Front Pediatr; 2018; 6():16. PubMed ID: 29479523
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Independent association of PD-L1 expression with noninactivated VHL clear cell renal cell carcinoma-A finding with therapeutic potential.
    Kammerer-Jacquet SF; Crouzet L; Brunot A; Dagher J; Pladys A; Edeline J; Laguerre B; Peyronnet B; Mathieu R; Verhoest G; Patard JJ; Lespagnol A; Mosser J; Denis M; Messai Y; Gad-Lapiteau S; Chouaib S; Belaud-Rotureau MA; Bensalah K; Rioux-Leclercq N
    Int J Cancer; 2017 Jan; 140(1):142-148. PubMed ID: 27623354
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The von Hippel-Lindau gene product inhibits vascular permeability factor/vascular endothelial growth factor expression in renal cell carcinoma by blocking protein kinase C pathways.
    Pal S; Claffey KP; Dvorak HF; Mukhopadhyay D
    J Biol Chem; 1997 Oct; 272(44):27509-12. PubMed ID: 9346879
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
    Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
    Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.
    Dornbusch J; Zacharis A; Meinhardt M; Erdmann K; Wolff I; Froehner M; Wirth MP; Zastrow S; Fuessel S
    PLoS One; 2013; 8(9):e76386. PubMed ID: 24086736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma.
    Lai Y; Zhao Z; Zeng T; Liang X; Chen D; Duan X; Zeng G; Wu W
    Cancer Cell Int; 2018; 18():31. PubMed ID: 29527128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrative analysis of dysregulated microRNAs and mRNAs in multiple recurrent synchronized renal tumors from patients with von Hippel-Lindau disease.
    Gattolliat CH; Couvé S; Meurice G; Oréar C; Droin N; Chiquet M; Ferlicot S; Verkarre V; Vasiliu V; Molinié V; Méjean A; Dessen P; Giraud S; Bressac-De-Paillerets B; Gardie B; Tean Teh B; Richard S; Gad S
    Int J Oncol; 2018 Oct; 53(4):1455-1468. PubMed ID: 30066860
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blockade of β2-Adrenergic Receptor Reduces Inflammation and Oxidative Stress in Clear Cell Renal Cell Carcinoma.
    Albiñana V; Recio-Poveda L; González-Peramato P; Martinez-Piñeiro L; Botella LM; Cuesta AM
    Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dissection of PD-L1 promoter reveals differential transcriptional regulation of PD-L1 in VHL mutant clear cell renal cell carcinoma.
    Kong SK; Kim BS; Lim H; Kim HJ; Kim YS
    Lab Invest; 2022 Apr; 102(4):352-362. PubMed ID: 34789838
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
    Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
    Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical significance of programmed death-1 and programmed death-ligand 1 expression in the tumor microenvironment of clear cell renal cell carcinoma.
    Mikami S; Mizuno R; Kondo T; Shinohara N; Nonomura N; Ozono S; Eto M; Tatsugami K; Takayama T; Matsuyama H; Kishida T; Oya M;
    Cancer Sci; 2019 Jun; 110(6):1820-1828. PubMed ID: 30972888
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein.
    Siemeister G; Weindel K; Mohrs K; Barleon B; Martiny-Baron G; Marmé D
    Cancer Res; 1996 May; 56(10):2299-301. PubMed ID: 8625303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential Expression of PD-L1 Between Sporadic and VHL-Associated Hereditary Clear-Cell Renal Cell Carcinoma and Its Correlation With Clinicopathological Features.
    Hong B; Cai L; Wang J; Liu S; Zhou J; Ma K; Zhang J; Zhou B; Peng X; Zhang N; Gong K
    Clin Genitourin Cancer; 2019 Apr; 17(2):97-104.e1. PubMed ID: 30522901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The in vitro and in vivo effects of re-expressing methylated von Hippel-Lindau tumor suppressor gene in clear cell renal carcinoma with 5-aza-2'-deoxycytidine.
    Alleman WG; Tabios RL; Chandramouli GV; Aprelikova ON; Torres-Cabala C; Mendoza A; Rogers C; Sopko NA; Linehan WM; Vasselli JR
    Clin Cancer Res; 2004 Oct; 10(20):7011-21. PubMed ID: 15501981
    [TBL] [Abstract][Full Text] [Related]  

  • 40. VHL and DNA damage repair pathway alterations as potential clinical biomarkers for first-line TKIs in metastatic clear cell renal cell carcinomas.
    Zhou J; Wang J; Kong W; Zhang J; Wu X; Huang J; Zheng J; Chen Y; Zhai W; Xue W
    Cell Oncol (Dordr); 2022 Aug; 45(4):677-687. PubMed ID: 35834099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.